Peptide Monograph

GHK-Cu

Copper Peptide — Glycyl-L-Histidyl-L-Lysine:Copper(II)

At a Glance

Mechanism of Action

GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide-copper complex first isolated from human plasma by Pickart and Thaler in 1973. The GHK tripeptide has a high affinity for copper(II) ions, and the resulting complex is present in human blood plasma at approximately 200 ng/mL in young adults, declining significantly with age to approximately 80 ng/mL by age 60.[1]

The biological activity of GHK-Cu is remarkably broad, encompassing multiple interconnected mechanisms. A central feature is its role as a wound healing accelerator. GHK-Cu stimulates the synthesis of collagen types I and III, glycosaminoglycans (including dermatan sulfate, chondroitin sulfate, and heparan sulfate), and small proteoglycans (decorin) in fibroblasts. Maquart et al. demonstrated that GHK-Cu stimulates both collagen synthesis and the accumulation of several extracellular matrix components critical for wound repair.[2]

GHK-Cu exerts significant anti-inflammatory effects by modulating cytokine signaling. It suppresses the expression of pro-inflammatory cytokines including transforming growth factor-beta (TGF-beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), while simultaneously promoting the expression of anti-inflammatory mediators. This dual immunomodulatory action helps resolve excessive inflammation that impedes tissue repair.[1][3]

The peptide also promotes angiogenesis (new blood vessel formation), which is critical for delivering oxygen and nutrients to healing tissues. GHK-Cu attracts immune cells, including macrophages and mast cells, to sites of injury, orchestrating the inflammatory-to-repair transition that characterizes successful wound healing.[2]

Perhaps the most striking aspect of GHK-Cu biology is its effect on gene expression. Pickart and Margolina conducted a comprehensive analysis using the Broad Institute's Connectivity Map database and identified that GHK-Cu modulates the expression of over 4,000 human genes, representing approximately 32% of the human genome. The affected gene networks include those involved in antioxidant defense, DNA repair, ubiquitin-proteasome system regulation, and suppression of pro-fibrotic and pro-inflammatory pathways.[3]

GHK-Cu additionally functions as an antioxidant, both through direct copper-mediated superoxide dismutase-like activity and through upregulation of endogenous antioxidant enzyme expression. The copper(II) ion in the complex is essential for many of these biological activities, serving as both a structural component and a catalytic cofactor.[1]

Evidence Summary

Topical Evidence (Human Studies)

Leyden et al. conducted controlled human studies demonstrating that topical GHK-Cu creams significantly improve skin firmness, elasticity, and clarity compared to placebo and vitamin C controls. In a 12-week facial study, GHK-Cu cream produced significant improvements in skin laxity and thickness as measured by ultrasound.[4]

Finkley et al. evaluated GHK-Cu in a double-blind, placebo-controlled trial for facial skin rejuvenation. After 12 weeks of daily application, subjects using GHK-Cu cream showed statistically significant improvements in skin density, thickness, and firmness compared to vehicle control, with clinical improvement visible in standardized photographs.[5]

Additional human studies have demonstrated that topical GHK-Cu accelerates wound healing following surgical procedures, reduces scar formation, and improves the cosmetic appearance of photo-damaged skin. These findings are consistent across multiple independent trials and form the basis for GHK-Cu's widespread use in cosmeceutical formulations.[1]

In Vitro and Animal Studies

Maquart et al. demonstrated in vitro that GHK-Cu stimulates the synthesis of collagen, glycosaminoglycans, and decorin in cultured fibroblasts. In an in vivo rat wound model, GHK-Cu-impregnated collagen matrices accelerated wound closure and increased the tensile strength of healed tissue compared to controls.[2]

Gene expression profiling by Pickart and Margolina revealed that GHK-Cu upregulates genes associated with tissue remodeling, antioxidant defense, and DNA repair, while downregulating genes linked to inflammation, fibrosis, and tissue destruction. The breadth of gene modulation (over 4,000 genes) suggests a fundamental role in tissue homeostasis rather than a single pharmacological target.[3]

Injectable Evidence

Published human clinical data for injectable (subcutaneous) GHK-Cu is extremely limited. The injectable use is based on extrapolation from the topical and in vitro evidence, combined with the reasoning that systemic delivery would produce more widespread tissue effects than localized topical application. No controlled human trial has evaluated subcutaneous GHK-Cu for any indication.

Primary Uses

Based on the available evidence, GHK-Cu has been investigated and used for the following applications:

• Skin rejuvenation and anti-aging (topical) — The best-supported application. Multiple human studies demonstrate improvements in skin firmness, elasticity, thickness, and clarity with topical GHK-Cu formulations.[4][5]
• Wound healing (topical and injectable) — Strong preclinical evidence for accelerated wound closure, enhanced collagen synthesis, and improved tissue remodeling. Topical applications have human clinical support; injectable use is extrapolated.[2]
• Hair growth stimulation — Topical GHK-Cu has been reported to enlarge hair follicle size and stimulate hair growth. Limited controlled data, primarily from cosmeceutical studies.[1]
• Systemic anti-aging (injectable) — Based on gene expression data showing upregulation of DNA repair, antioxidant defense, and tissue remodeling pathways. Entirely theoretical for injectable use; no clinical validation.[3]
• Anti-inflammatory support (injectable) — GHK-Cu suppresses pro-inflammatory cytokines in vitro. Self-experimenters report systemic anti-inflammatory effects via injection, but no controlled human data supports this application.
• Post-surgical recovery — Topical GHK-Cu is used clinically to accelerate healing after laser resurfacing, chemical peels, and surgical procedures.[1]

Contraindications

Standard Protocols

Common Stacks & Synergies

GHK-Cu is commonly combined with other peptides and compounds in both topical and injectable protocols. The following combinations are frequently discussed, though controlled studies evaluating combined efficacy are limited:

• GHK-Cu + BPC-157 — The most commonly discussed injectable combination. The rationale is that BPC-157's pro-angiogenic and growth-factor-mediated healing complements GHK-Cu's collagen-synthesis and extracellular-matrix-remodeling effects for comprehensive tissue repair.
• GHK-Cu + TB-500 — TB-500 promotes actin upregulation and cell migration. Combined with GHK-Cu's matrix-remodeling and anti-inflammatory properties, this stack targets multiple phases of the wound healing cascade.
• GHK-Cu + Retinol (topical) — In cosmeceutical protocols, GHK-Cu is often paired with retinoids for synergistic skin rejuvenation. GHK-Cu provides collagen stimulation and anti-inflammatory effects that may mitigate retinol-induced irritation.
• GHK-Cu + Vitamin C (topical) — Ascorbic acid is a cofactor for collagen synthesis. Combining with GHK-Cu provides both the stimulatory signal and the biochemical substrate for enhanced collagen production.

Preparation & Administration

Injectable GHK-Cu is supplied as a lyophilized (freeze-dried) powder, typically in vials containing 50 mg or 100 mg. It must be reconstituted with bacteriostatic water (BAC water) before injection. Topical formulations are available as commercially prepared creams, serums, and gels.

Reconstitution (Injectable)

For a standard 50 mg vial reconstituted with 5 mL of bacteriostatic water, the resulting concentration is 10 mg/mL. Each 0.1 mL (10 units on a standard insulin syringe) delivers 1 mg. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. For systemic protocols, inject into abdominal subcutaneous tissue. For localized tissue repair, inject as close to the target area as anatomically practical. Rotate injection sites to avoid lipodystrophy and localized skin discoloration (a known effect of copper deposition). For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Topical Application

Apply topical GHK-Cu formulations to clean, dry skin. For anti-aging purposes, apply after cleansing and before heavier moisturizers or sunscreen. For wound healing applications, apply to the wound margin and surrounding tissue. GHK-Cu may impart a slight blue tint to the skin at higher concentrations due to the copper(II) ion; this typically fades within hours.

Side Effects & Adverse Events

Topical

Topical GHK-Cu is generally very well tolerated. In clinical studies, adverse events were uncommon and mild:[4][5]

• Mild, transient skin irritation at application site (uncommon)
• Temporary blue-green skin discoloration at high concentrations (cosmetic, reversible)
• Contact dermatitis (rare; discontinue if observed)

Injectable (self-reported, unverified)

• Injection site irritation — Redness, swelling, and mild pain at the injection site (most commonly reported)
• Skin discoloration — Localized blue-green discoloration at injection sites due to copper deposition. May persist for days to weeks. Rotating injection sites is essential.
• Nausea — Mild nausea reported by some users, particularly at higher doses
• Metallic taste — Occasionally reported, likely related to copper
• Lightheadedness — Infrequently reported

No serious adverse events have been reported in published literature for either topical or injectable GHK-Cu, though the absence of systematic pharmacovigilance for the injectable form means rare adverse effects could go undetected.

Drug Interactions

No formal drug interaction studies have been conducted with GHK-Cu. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:

• Copper chelators (penicillamine, trientine) — These agents are used to treat copper overload (e.g., Wilson's disease) by binding and removing copper. They would be expected to chelate the copper from GHK-Cu, potentially neutralizing its biological activity. Concurrent use is pharmacologically contradictory.
• Zinc supplements (high-dose) — Zinc and copper compete for intestinal absorption and can create reciprocal deficiencies. High-dose zinc supplementation may reduce copper bioavailability and could theoretically attenuate systemic GHK-Cu effects.
• Anticoagulants — GHK-Cu promotes angiogenesis. Theoretical interactions with anticoagulant medications exist, though clinical significance is unknown.
• Immunosuppressants — GHK-Cu modulates immune cell recruitment and cytokine expression. Interactions with immunosuppressive agents (e.g., cyclosporine, tacrolimus, corticosteroids) are theoretically possible but uncharacterized.
• Topical retinoids — When used together topically, GHK-Cu may mitigate retinoid-induced skin irritation. This is generally considered a beneficial interaction, though not rigorously studied in controlled trials.

Storage & Handling

Do not freeze reconstituted solution. The reconstituted solution may have a slight blue tint due to the copper(II) ion; this is normal. If the solution appears cloudy, contains particulate matter, or shows an unusual color change, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.

Legal & Regulatory Status

• Topical (Cosmetic) — GHK-Cu is a legal cosmetic ingredient in the United States, European Union, and most other jurisdictions. It is listed as "Copper Tripeptide-1" in the International Nomenclature of Cosmetic Ingredients (INCI) and is widely used in commercial skincare products.
• Injectable (Research Chemical) — Injectable GHK-Cu is not FDA-approved for any indication. It is sold as a research chemical under the designation "not for human consumption." No NDA or IND for injectable GHK-Cu is publicly known to be active.
• WADA (World Anti-Doping Agency) — GHK-Cu is not specifically listed on the WADA Prohibited List as of 2026. However, the broad category S0 ("non-approved substances") could theoretically apply to injectable use.
• European Union — Topical Copper Tripeptide-1 is an approved cosmetic ingredient under EU Cosmetics Regulation. Injectable use falls under research chemical classification.
• Australia (TGA) — Topical GHK-Cu is available in cosmetic products. Injectable form is not approved for therapeutic use.

Open Questions

Despite decades of research on GHK-Cu, significant gaps remain, particularly for injectable applications:

• Injectable human clinical validation — The most fundamental gap. No controlled human trial has evaluated subcutaneous GHK-Cu for any indication. All injectable claims are extrapolated from topical, in vitro, and animal data.
• Systemic pharmacokinetics — The half-life, volume of distribution, tissue penetration, and copper biodistribution following subcutaneous injection have not been characterized in humans.
• Copper accumulation risk — With chronic injectable use, the potential for copper accumulation in tissues (particularly liver) has not been assessed. This is a meaningful safety concern given the known toxicity of copper overload.
• Cancer risk / benefit — Gene expression data shows GHK-Cu upregulates both tissue remodeling genes (potentially pro-tumorigenic) and tumor suppressor genes (potentially anti-tumorigenic). The net effect on cancer risk is unknown and represents a critical safety question.[3]
• Optimal injectable dosing — Current injectable dosing protocols are not derived from dose-finding studies and may be subtherapeutic or supratherapeutic.
• Topical vs. injectable comparative efficacy — Whether injectable administration provides meaningful additional benefit over topical use for skin and wound-healing applications is unknown.

Bibliography

1. Pickart L, Vasquez-Soltero JM, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID:26236730.
2. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. "Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+." FEBS Lett. 1988;238(2):343-6. doi:10.1016/0014-5793(88)80509-X. PMID:3169264.
3. Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID:29986520.
4. Leyden JJ, Grove GL, Grove MJ, Thorne EG, Lufrano L. "Treatment of photodamaged facial skin with topical tretinoin." J Am Acad Dermatol. 1989;21(3 Pt 2):638-44. doi:10.1016/S0190-9622(89)70231-0. PMID:2778124.
5. Finkley MB, Appa Y, Bhandarkar S. "Copper peptide and skin." In: Elsner P, Maibach HI, eds. Cosmeceuticals and Active Cosmetics: Drugs vs. Cosmetics. 2nd ed. New York: Marcel Dekker; 2005:549-563.
6. Pickart L. "The human tri-peptide GHK and tissue remodeling." J Biomater Sci Polym Ed. 2008;19(8):969-88. doi:10.1163/156856208784909435. PMID:18644225.
7. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, Monboisse JC, Gillery P, Borel JP. "In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds." J Clin Invest. 1993;92(5):2368-76. doi:10.1172/JCI116842. PMID:8227353.